54527-84-3 Nicardipine HCl AKSci J50459
 
 
Loading Please Wait...
  J50459    AKSci Bulk Reagent
Nicardipine HCl, 95%, for synthesis
 
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)methyl-2-[methyl(phenylmethyl)amino]-3,5-pyridinedicarboxylic acid ethyl ester hydrochloride
IDENTITY
CAS Number:54527-84-3
MDL Number:MFCD00057327
MF:C26H30ClN3O6
MW:515.99
EINECS:259-198-4
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%, for synthesis
Physical Form (at 20°C):Solid
Melting Point:179-187°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
UN #:UN2811
Hazard Class:6.1; Poison
Packing Group:III
A hazmat fee may apply depending on the amount ordered, as indicated in the list of package sizes.

BIOLOGICAL INFO
Solubility:MeOH; DMSO: ~1mg/mL
Application(s):Calcium channel blockade
Form:HCl salt

REVIEW
 Nicardipine hydrochloride is a racemic, dihydropyridine calcium-channel blocker for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations.

REFERENCES
[1]Murakami, Masuo; Takahashi, Kozo; Iwanami, Masaru; Fujimoto, Masaharu; Shibanuma, Tadao; Kawai, Ryutaro; Takenaka, Toichi Spasmolytic and vasodilatory 1,4-dihydro-4-phenyl-3,5-pyridinedicarboxylates Ger. Offen. (1974), DE 2407115 A1 19741010.
[2] Iwanami, Masaru; Shibanuma, Tadao; Fujimoto, Masaharu; Kawai, Ryutaro; Tamazawa, Kazuharu; Takenaka, Toichi; Takahashi, Kozo; Murakami, Masuo Synthesis of new water-soluble dihydropyridine vasodilators Chemical & Pharmaceutical Bulletin (1979), 27(6), 1426-40.
[3] Antoncic, Ljubo; Jazbec, Iztok; Kocjan, Darko; Krivec, Ivana Process for the preparation of 2-(benzylmethylamino)ethyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate and its hydrochloride salt U.S. (1988), US 4769465 A 19880906.
[4] Sorkin EM, Clissold SP. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987 Apr;33(4):296-345.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H301+H311+H331

Precautionary Statements
P261; P264; P270; P271; P280; P301+P310; P302+P352; P304+P340; P312; P322; P330; P361; P363; P403+P233; P405; P501

Current as of December 6, 2023


Download SDS Request COA

⚠️
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Calcium Channel Blockers


PubChem